In Vivo Bone Effects of a Novel Bisphosphonate‐EP4a Conjugate Drug (C3) for Reversing Osteoporotic Bone Loss in an Ovariectomized Rat Model

Pathological bone loss is a regular feature of postmenopausal osteoporosis, and the microstructural changes along with the bone loss make the individual prone to getting hip, spine, and wrist fractures. We have developed a new conjugate drug named C3, which has a synthetic, stable EP4 agonist (EP4a)...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheikh, Zeeshan, Chen, Gang, Al‐Jaf, Faik, Thévenin, Marion, Banks, Kate, Glogauer, Michael, Young, Robert N, Grynpas, Marc D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894726/
https://www.ncbi.nlm.nih.gov/pubmed/31844825
http://dx.doi.org/10.1002/jbm4.10237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894726/
https://www.ncbi.nlm.nih.gov/pubmed/31844825
http://dx.doi.org/10.1002/jbm4.10237

Ejemplares similares